Home/Compounds/Khavinson short peptides (Cytogens/'peptide bioregulators': Pinealon EDR, Vilon KE, Livagen, etc.)
● TIER 3 — Information onlyGRADE CBioregulators
Khavinson short peptides (Cytogens/'peptide bioregulators': Pinealon EDR, Vilon KE, Livagen, etc.)
Origin: Russia. Citations verified: partial. 0 human study record(s) in the FitClinicMD studies database.
GOALS · Longevity
FDA status
Not an FDA-approved product
Compounding (503A/503B)
Status varies — see notes
DEA
Not listed as controlled
WADA (sport)
Not specified
Mechanism
Hypothesis that di-/tripeptides enter cells and bind histones/DNA to alter gene expression. Khavinson et al. 2020 review proposes Pinealon (Glu-Asp-Arg) binds histones/RNA/DNA and modulates MAPK/ERK, caspase-3/p53, SOD2/GPX1 and other pathways in Alzheimer's models 1; a 2022 systematic review on peptide regulation of gene expression 2.
Human evidence
No qualifying human studies are catalogued for Khavinson short peptides (Cytogens/'peptide bioregulators': Pinealon EDR, Vilon KE, Livagen, etc.) in our database. It is listed here for transparency and reference only.
Reference only. This page summarizes publicly available regulatory and research information about Khavinson short peptides (Cytogens/'peptide bioregulators': Pinealon EDR, Vilon KE, Livagen, etc.). It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.